PD-L1 expression in immune cells is a favorable prognostic factor for nasopharyngeal carcinoma
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessAttribution-NonCommercial-ShareAlike 4.0 Internationalhttps://creativecommons.org/licenses/by-nc-sa/4.0/Tarih
2021Yazar
Şahinli, HayriyeAkyürek, Nalan
Yılmaz, Mukaddes
Kandemir, Olcay
Ocak Duran, Ayşe
Kulaçoğlu, Sezer
Uçar, Gökhan
Acar, Elif
Özet, Ahmet
Gümüş, Mahmut
Çakmak Öksüzoğlu, Ömür Berna
Yıldırım Özdemir, Nuriye
Üst veri
Tüm öğe kaydını gösterKünye
Şahinli, H., Akyürek, N., Yılmaz, M., Kandemir, O., Ocak Duran, A., Kulaçoğlu, S. ... Yıldırım Özdemir, N. (2021). PD-L1 expression in immune cells is a favorable prognostic factor for nasopharyngeal carcinoma. Indian Journal of Cancer, 58(4), 561-566. https://dx.doi.org/10.4103/ijc.IJC_459_19Özet
Background: Programmed death-ligand 1 (PD-L1) has been determined as a reliable prognostic factor for various malignancies. In this study, we aimed to determine the prognostic effect of PD-L1 expression in tumor-infiltrating immune cells (TIICs) of nasopharyngeal carcinoma (NPC) patients.Methods: Seventy patients diagnosed with non-metastatic NPC were included in the study. PD-L1 expression on immune cells was analyzed by immunohistochemical method. Patients were categorized into two groups according to the PD-L1 expression level in TIICs (level of PD-L1 staining ≥5% positive vs <5% negative).Results: Median follow-up period was 34 months (range = 1 - 188). 1 and 2 years survival rate were found as 75% and 63% in PD-L1 negative TIICs group (47%), and 85% and 83% in PD-L1 positive TIICs group (53%), respectively. PD-L1 positivity in immune cells (ICs) was detected in 53% of the patients. The survival rate was found better in the PD- L1 positive group compared to the negative group (P = 0.049).Discussion: In conclusion, the survival rate was found significantly better in the PD-L1 positive TIICs group, compared to the negative group.
Scopus Q Kategorisi
Q3Kaynak
Indian Journal of CancerCilt
58Sayı
4Koleksiyonlar
- Makale Koleksiyonu [3635]
- PubMed İndeksli Yayınlar Koleksiyonu [4026]
- Scopus İndeksli Yayınlar Koleksiyonu [6243]
- WoS İndeksli Yayınlar Koleksiyonu [6402]